XOMA Corp (XOMA)
23.69
+0.79
(+3.45%)
USD |
NASDAQ |
Jun 28, 16:00
23.32
-0.37
(-1.56%)
After-Hours: 20:00
XOMA Research and Development Expense (Annual): 0.143M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.143M |
| December 31, 2022 | 0.153M |
| December 31, 2021 | 0.171M |
| December 31, 2020 | 0.17M |
| December 31, 2019 | 1.253M |
| December 31, 2018 | 1.682M |
| December 31, 2017 | 7.875M |
| December 31, 2016 | 44.23M |
| December 31, 2015 | 70.85M |
| December 31, 2014 | 80.75M |
| December 31, 2013 | 74.85M |
| December 31, 2012 | 68.47M |
| December 31, 2011 | 68.14M |
| December 31, 2010 | 77.41M |
| December 31, 2009 | 58.13M |
| Date | Value |
|---|---|
| December 31, 2008 | 82.58M |
| December 31, 2007 | 66.22M |
| December 31, 2006 | 52.09M |
| December 31, 2005 | 39.90M |
| December 31, 2004 | 49.78M |
| December 31, 2003 | 61.06M |
| December 31, 2002 | 42.62M |
| December 31, 2001 | 35.93M |
| December 31, 2000 | 30.01M |
| December 31, 1999 | 41.50M |
| December 31, 1998 | 43.80M |
| December 31, 1997 | 29.90M |
| December 31, 1996 | 26.40M |
| December 31, 1995 | 22.10M |
| December 31, 1994 | 27.30M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
0.143M
Minimum
2023
1.253M
Maximum
2019
0.378M
Average
0.17M
Median
2020
Research and Development Expense (Annual) Benchmarks
| Viracta Therapeutics Inc | 33.37M |
| AnaptysBio Inc | 132.28M |
| Cue Biopharma Inc | 40.80M |
| NovaBay Pharmaceuticals Inc | 0.068M |
| Palatin Technologies Inc | 22.63M |